AstraZeneca Pharma India Limited

ASTRAZEN

INE203A01020

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 04:10:00 2026-01-20 am EST			5-day change	1st Jan Change
8,257.85 ^INR	-0.36%		+0.59%	-8.32%

Dec. 17	Astrazeneca Pharma India receives permission to import datopotamab deruxtecan powder to India	RE
Nov. 27	AstraZeneca Pharma India gets tax order with estimated tax impact of 33 million rupees	RE

AstraZeneca Pharma India, Sun Pharma Sign Second Brand Deal for SZC in India

Published on 11/17/2025 at 07:16 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AstraZeneca Pharma India Limited

Dec. 17	Astrazeneca Pharma India receives permission to import datopotamab deruxtecan powder to India	RE
Nov. 27	AstraZeneca Pharma India gets tax order with estimated tax impact of 33 million rupees	RE
Nov. 17	AstraZeneca Pharma India, Sun Pharma Sign Second Brand Deal for SZC in India	MT
Nov. 17	Astrazeneca Pharma India and Sun Pharma partner for hyperkalaemia treatment	RE
Nov. 17	AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited Announce Partnership to Help Patients Living with Hyperkalaemia in India	CI
Nov. 10	Astrazeneca Pharma India Limited Announces Resignation of Ms. Manasa. R, as Company Secretary, Effective November 28, 2025	CI
Nov. 07	AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
Nov. 07	Astrazeneca Pharma India Sept-quarter PAT 542.2 million rupees	RE
25-10-17	Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer	CI
25-10-17	Amgen and AstraZeneca Announce FDA Approves TEZSPIRE®? for Chronic Rhinosinusitis with Nasal Polyps	CI
25-10-15	AstraZeneca Boosts U.S. Manufacturing with Texas Facility Expansion	DJ
25-10-03	Astrazeneca Pharma India Ltd - receives permission to import Enhertu	RE
25-09-12	Astrazeneca Pharma India gets show cause notice from National Pharmaceutical Pricing Authority	RE
25-09-12	AstraZeneca Pharma India Limited Receives a Show Cause Notice from National Pharmaceutical Pricing Authority	CI
25-09-02	Astrazeneca Pharma India surrenders manufacturing license	RE
25-09-02	Astrazeneca Pharma India Limited Announces Surrender of Its Manufacturing License Which Was Valid Up to December 2027	CI
25-08-18	Astrazeneca Pharma India Limited Approves Declaration for Financial Year 2024-25	CI
25-08-18	Astrazeneca Pharma India Limited Appoints Mr. Praveen Rao Akkinepally as an Director	CI
25-08-14	AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-14	Astrazeneca Pharma India June-quarter pat 558.3 million rupees	RE
25-06-13	AstraZeneca Pharma India Limited Appoints Praveen Rao Akkinepally as India Managing Director, Effective 1 July 2025	CI
25-06-09	Astrazeneca Pharma India Says Sanjeev Kumar Panchal Has Offered To Resign As MD	RE
25-06-09	AstraZeneca Pharma India Limited Announces Resignation of Sanjeev Kumar Panchal as Managing Director, Effective June 30, 2025	CI
25-06-09	AstraZeneca Pharma India Limited Announces Board Changes	CI
25-06-02	INDIA STOCKS-IT, metals weigh on India benchmarks as tariff worries outweigh growth optimism	RE

Chart AstraZeneca Pharma India Limited

Duration

Period

ASTRAZEN: Dynamic Chart

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Companyâs DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

Employees

600

Sector

Pharmaceuticals

Calendar

Jan. 20 - Investor Meeting - ICICI Prudential Asset Management Co Ltd

More about the company